Eric got his PhD in 2004 from the University of Alberta studying the molecular mechanisms of bile acid metabolism. He then went to the University of Cincinnati for a PostDoc studying the mechanisms of macronutrient absorption in the gut and its role in disease. In 2008 Eric joined the newly formed Ardelyx, a biotech company devoted to discovering small molecule drugs that are non-absorbed and affect human health from the gut. Eric was lead in vivo pharmacologist for 2 programs that went to the clinic. Eric was then recruited in 2014 to Relypsa to lead in vivo pharmacology in drug discovery for the research group. He joined Recursion with a commitment to advance the drug discovery pipeline and help achieve the company’s potential for an audacious portfolio. Eric has 3 patents and16 peer-reviewed research publications throughout his career. He enjoys cooking, history, and running.
Are you Recursion ready?
Join our passionate and highly cross-functional team—and help us radically improve people’s lives.